Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.87 |
| ▸ | FAAH | O00519 | 4/20 | 0.61 |
| ▸ | CNR1 | P21554 | 2/20 | 0.61 |
| ▸ | CNR2 | P34972 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.55 |
| ▸ | ITGAL | P20701 | 3/20 | 0.55 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28341177 | 1.00 | SLC6A5 (0.87) | SLC6A5FAAHCNR1CNR2EPHX2 | |
| SCHEMBL15649758 | 1.00 | SLC6A5 (0.87) | SLC6A5FAAHCNR1CNR2EPHX2 | |
| SCHEMBL17203892 | 1.00 | SLC6A5 (0.87) | SLC6A5FAAHCNR1CNR2EPHX2 | |
| SCHEMBL9664374 | 1.00 | SLC6A5 (0.87) | SLC6A5FAAHCNR1CNR2EPHX2 | |
| SCHEMBL13279669 | 1.00 | SLC6A5 (0.87) | SLC6A5FAAHCNR1CNR2EPHX2 | |
| SCHEMBL17817155 | 1.00 | SLC6A5 (0.87) | SLC6A5FAAHCNR1CNR2EPHX2 | |
| SCHEMBL15650015 | 1.00 | SLC6A5 (0.87) | SLC6A5FAAHCNR1CNR2EPHX2 | |
| SCHEMBL17204083 | 1.00 | SLC6A5 (0.87) | SLC6A5FAAHCNR1CNR2EPHX2 | |
| SCHEMBL22034112 | 1.00 | SLC6A5 (0.87) | SLC6A5FAAHCNR1CNR2EPHX2 | |
| SCHEMBL9665932 | 1.00 | SLC6A5 (0.87) | SLC6A5FAAHCNR1CNR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2021-03-25 | — | — | US | claimed |
| EP-3006045-B3 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2021-03-17 | — | — | EP | claimed |
| EP-3773475-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH (AT) | 2021-02-17 | — | — | EP | claimed |
| WO-2019193204-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2019-10-10 | — | — | WO | claimed |
| EP-3204045-B1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-12-05 | — | — | EP | claimed |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2018-10-04 | — | — | US | claimed |
| WO-2018065634-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE NASAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-04-12 | — | — | WO | claimed |
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2017-10-26 | — | — | US | claimed |
| EP-3204045-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | Cyprumed GmbH (AT) | 2017-08-16 | — | — | EP | claimed |
| CN-106794252-A | Pharmaceutical formulations for oral delivery of peptide or protein drugs | 塞浦路迈德有限责任公司 | 2017-05-31 | — | — | CN | claimed |
| WO-2017060500-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2017-04-13 | — | — | WO | claimed |
| EP-3006045-B1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2017-04-12 | — | — | EP | claimed |
| WO-2016055550-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2016-04-14 | — | — | WO | claimed |
| CN-103458873-B | For the aminoacid of the fatty-acylation of oral peptide delivery | NOVO NORDISK A/S (DK) | 2016-04-13 | — | — | CN | claimed |
| EP-3006045-A1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | Cyprumed GmbH (AT) | 2016-04-13 | — | — | EP | claimed |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2014-02-27 | — | — | US | claimed |
| CN-103458873-A | Fatty acid acylated amino acids for oral peptide delivery | NOVO NORDISK AS | 2013-12-18 | — | — | CN | claimed |
| CN-103432091-A | Improved-performance tablet and preparation method thereof | ZHONG SHUGUANG | 2013-12-11 | — | — | CN | claimed |
| EP-4414063-B1 | NANONETS FOR REMOVAL OF CONTAMINANTS FROM AQUEOUS SOLUTIONS, KITS THEREFOR AND METHODS OF THEIR USE | CARBONET NANOTECHNOLOGIES INC (CA) | 2026-04-15 | — | — | EP | disclosed |
| EP-2111860-A1 | INFLAMMATION INHIBITOR COMPRISING ZINC SALT OF ACYLAMINO ACID | Ajinomoto Co., Inc. (JP) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | SLC30A5, SLC30A6, SON | SLC6A5 283/4885FAAH 4519/4885CNR1 4051/4885 |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | SLC30A5, SLC39A11, SLC30A6 | SLC6A5 85/4885FAAH 4365/4885CNR1 3830/4885 |
| US-20210087250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | VIP, PTMS, VASP | SLC6A5 154/4885FAAH 3710/4885CNR1 3257/4885 |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | SLC27A1, SLC27A2, FABP2 | SLC6A5 1468/4885FAAH 63/4885CNR1 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.